Back to top

Image: Bigstock

Clovis Oncology, Inc.

Read MoreHide Full Article

Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca. It is not only the first approved product in Clovis’ portfolio, but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ top line, going forward. Rubraca is also under review in the EU for a comparable ovarian cancer indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Meanwhile, Clovis is looking to expand Rubraca’s label into additional indication like prostrate, breast and pancreatic cancers, among others. Also, shares of Clovis outperformed the industry in the past one year. Estimates have been stable ahead of Q4 results. However, Clovis’ dependence on Rubraca alone for growth is a cause for concern.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Clovis Oncology, Inc. (CLVS) - free report >>

Published in